Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00406653
Registration number
NCT00406653
Ethics application status
Date submitted
1/12/2006
Date registered
4/12/2006
Date last updated
14/09/2010
Titles & IDs
Public title
A Study of Abatacept in Patients With Active Crohn's Disease
Query!
Scientific title
A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Crohn's Disease (CD) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Query!
Secondary ID [1]
0
0
IM101-084
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - abatacept
Treatment: Drugs - placebo
Treatment: Drugs - abatacept
Experimental: 1 - 4 arms for induction period
2 arms for maintenance period
Placebo Comparator: 2 - 4 arms for induction period
2 arms for maintenance period
Other: abatacept - 1 arm for open-label extension phase
Treatment: Drugs: abatacept
Dextrose 5% in water, intravenous (IV).
Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;
3 mg/kg on days IP-1, IP-15,IP-29, IP-57;
~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,
or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57.
Induction Period 3 months
Maintenance Period 12 months
Treatment: Drugs: placebo
Normal saline, IV, 0 mg/kg, every 28 days.
Induction Period 3 months
Maintenance Period 12 months
Treatment: Drugs: abatacept
~10 mg/kg, every 28 days.
Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85
Query!
Assessment method [1]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [1]
0
0
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12).
Query!
Primary outcome [2]
0
0
Maintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI <150) at Day MP-365 (12 Months)
Query!
Assessment method [2]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [2]
0
0
Day MP-365 (12 months) of maintenance therapy
Query!
Primary outcome [3]
0
0
Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs
Query!
Assessment method [3]
0
0
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Query!
Timepoint [3]
0
0
Between Day OL-1 and Day OL-617
Query!
Primary outcome [4]
0
0
OL; Number of Participants With Adverse Events (AEs) of Special Interest
Query!
Assessment method [4]
0
0
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Query!
Timepoint [4]
0
0
Between Day OL-1 and Day OL-617
Query!
Secondary outcome [1]
0
0
IP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome)
Query!
Assessment method [1]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [1]
0
0
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Query!
Secondary outcome [2]
0
0
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship
Query!
Assessment method [2]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [2]
0
0
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Query!
Secondary outcome [3]
0
0
IP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ)
Query!
Assessment method [3]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-Baseline - Baseline value.
Query!
Timepoint [3]
0
0
Baseline, Day IP-85
Query!
Secondary outcome [4]
0
0
IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs
Query!
Assessment method [4]
0
0
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Query!
Timepoint [4]
0
0
Day IP-1 through Day IP-85
Query!
Secondary outcome [5]
0
0
IP; Number of Participants With Adverse Events (AEs) of Special Interest
Query!
Assessment method [5]
0
0
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Query!
Timepoint [5]
0
0
Day IP-1 through Day IP-85
Query!
Secondary outcome [6]
0
0
IP; Number of Participants With Positive Antibody Response to Abatacept (ABA)
Query!
Assessment method [6]
0
0
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition identified specific anti-ABA reactivity. Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig) category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Query!
Timepoint [6]
0
0
For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85); For participants treated in OL directly after IP: Day IP-1 to Day OL-1; For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)
Query!
Secondary outcome [7]
0
0
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)
Query!
Assessment method [7]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [7]
0
0
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Query!
Secondary outcome [8]
0
0
IP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF
Query!
Assessment method [8]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [8]
0
0
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Query!
Secondary outcome [9]
0
0
IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship
Query!
Assessment method [9]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [9]
0
0
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Query!
Secondary outcome [10]
0
0
MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due To AEs
Query!
Assessment method [10]
0
0
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Query!
Timepoint [10]
0
0
Between Day IP-85 and Day MP-365
Query!
Secondary outcome [11]
0
0
MP; Number of Participants With Adverse Events (AEs) of Special Interest:
Query!
Assessment method [11]
0
0
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Query!
Timepoint [11]
0
0
Between Day IP-85 and Day MP-365
Query!
Secondary outcome [12]
0
0
MP; Number of Participants With Positive Antibody Response to Abatacept
Query!
Assessment method [12]
0
0
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Query!
Timepoint [12]
0
0
For participants not entering OL: All measurements after Day MP-1 (including follow-up visits); For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1)
Query!
Secondary outcome [13]
0
0
MP; Number of Participants With CDAI-defined Clinical Response at Day MP-365.
Query!
Assessment method [13]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [13]
0
0
Day MP-365
Query!
Secondary outcome [14]
0
0
MP; Number of Participants in CDAI-defined Clinical Remission at Both Day MP-169 and Day MP-365
Query!
Assessment method [14]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [14]
0
0
Day MP-169
Query!
Secondary outcome [15]
0
0
MP; Change From Baseline to Day MP-365 in Short Form-36 (SF-36)
Query!
Assessment method [15]
0
0
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
Query!
Timepoint [15]
0
0
Baseline, Day MP-365
Query!
Secondary outcome [16]
0
0
MP; Change From Baseline to Day MP-365 in Inflammatory Bowel Disease Questionnaire (IBDQ)
Query!
Assessment method [16]
0
0
The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-baseline - Baseline value.
Query!
Timepoint [16]
0
0
Baseline, Day MP-365
Query!
Secondary outcome [17]
0
0
MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among All Participants Who Received Baseline Corticosteroid Therapy
Query!
Assessment method [17]
0
0
Participants who received corticosteroid therapy (e.g. prednisone or budesonide) were to maintain a stable dose until Day MP-1. On or after Day MP-1, a recommended tapering regimen of corticosteroid therapy was planned if the participant was in remission (i.e., CDAI score < 150), or if the participant's condition had satisfactorily improved according to investigators clinical assessment. Other CD therapy was to remain at a stable dose throughout the Maintenance Period, with the exception of decreases due to drug-related toxicities.
Query!
Timepoint [17]
0
0
Day MP-365
Query!
Secondary outcome [18]
0
0
MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among Participants Who Received Baseline Corticosteroid Therapy and Who Achieved CDAI-Defined Clinical Remission
Query!
Assessment method [18]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score is based partly on entries from participant's Diary (7 days before evaluation) which is kept while on study. CDAI scores range from 0 to ~600. Clinical response=CDAI reduction =100 or absolute CDAI <150. Clinical remission=CDAI <150. Moderate to severe disease=CDAI =220 and =450.
Query!
Timepoint [18]
0
0
Day MP-365
Query!
Secondary outcome [19]
0
0
MP; Number of Participants With CDAI-Defined Clinical Response Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)
Query!
Assessment method [19]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [19]
0
0
Day MP-365
Query!
Secondary outcome [20]
0
0
MP; Number of Participants in CDAI-Defined Clinical Remission Among Participants With Inadequate Response and/or Intolerance to Anti-TNF
Query!
Assessment method [20]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [20]
0
0
Day MP-365
Query!
Secondary outcome [21]
0
0
OL; Number of Participants Who Were Not On Background Corticosteroid Therapy Among All Participants Who Received Baseline Corticosteroid Therapy
Query!
Assessment method [21]
0
0
Background corticosteroid therapy included prednisone or budesonide.
Query!
Timepoint [21]
0
0
Between Day OL-1 and Day OL-617
Query!
Secondary outcome [22]
0
0
OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-169
Query!
Assessment method [22]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [22]
0
0
Day OL-169
Query!
Secondary outcome [23]
0
0
OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-365
Query!
Assessment method [23]
0
0
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to ~600 points. Clinical response=CDAI reduction =100 points or absolute CDAI <150 points. Clinical remission=CDAI <150 points. Moderate to severe disease=CDAI =220 and =450 points.
Query!
Timepoint [23]
0
0
Day OL-365
Query!
Secondary outcome [24]
0
0
OL; Number of Participants With Positive Antibody Response to Abatacept
Query!
Assessment method [24]
0
0
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Query!
Timepoint [24]
0
0
For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)
Query!
Secondary outcome [25]
0
0
OL; Number of Participants With Pharmacogenomic Marker Activity
Query!
Assessment method [25]
0
0
Changes in the expression of individual ribonucleic acid (RNA) transcripts were to be evaluated from whole blood using both microarray transcriptional profiling and quantitative polymerase chain reaction (PCR) methods. Peripheral RNA transcriptional profiling was to be used only to identify individual RNA transcripts that differ in expression with respect to time, treatment and outcome.
Query!
Timepoint [25]
0
0
Between Day OL-1 and Day OL-617
Query!
Eligibility
Key inclusion criteria
- 18 years or older
- have had Crohn's Disease for at least 3 months
- moderate to severely active Crohn's Disease
- have had an inadequate response or intolerance to other Crohn's Disease treatments
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
451
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - Garran
Query!
Recruitment hospital [2]
0
0
Local Institution - Camperdown
Query!
Recruitment hospital [3]
0
0
Local Institution - Herston
Query!
Recruitment hospital [4]
0
0
Local Institution - South Brisbane
Query!
Recruitment hospital [5]
0
0
Local Institution - Bedford Park
Query!
Recruitment hospital [6]
0
0
Local Institution - Launceston
Query!
Recruitment hospital [7]
0
0
Local Institution - Box Hill
Query!
Recruitment hospital [8]
0
0
Local Institution - Fitzroy
Query!
Recruitment hospital [9]
0
0
Local Institution - South Ballarat
Query!
Recruitment hospital [10]
0
0
Local Institution - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [6]
0
0
7250 - Launceston
Query!
Recruitment postcode(s) [7]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [8]
0
0
3065 VIC - Fitzroy
Query!
Recruitment postcode(s) [9]
0
0
3350 - South Ballarat
Query!
Recruitment postcode(s) [10]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oklahoma
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Bonheiden
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Leuven
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Roeselare
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Bahia
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Goias
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Parana
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Rio Grande Do Sul
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Sao Paulo
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Alberta
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
British Columbia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Newfoundland and Labrador
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Nova Scotia
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Ontario
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Quebec
Query!
Country [35]
0
0
Czech Republic
Query!
State/province [35]
0
0
Ceske Budejovice
Query!
Country [36]
0
0
Denmark
Query!
State/province [36]
0
0
Aalborg
Query!
Country [37]
0
0
Denmark
Query!
State/province [37]
0
0
Arhus C
Query!
Country [38]
0
0
Denmark
Query!
State/province [38]
0
0
Hvidovre
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Odense C
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Amiens Cedex 1
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Lille Cedex
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Nice
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Paris Cedex 10
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Pessac
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Toulouse Cedex
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Kiel
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Muenster
Query!
Country [48]
0
0
India
Query!
State/province [48]
0
0
Andhra Pradesh
Query!
Country [49]
0
0
India
Query!
State/province [49]
0
0
Hyderabad
Query!
Country [50]
0
0
India
Query!
State/province [50]
0
0
Mangalore
Query!
Country [51]
0
0
India
Query!
State/province [51]
0
0
Manipal
Query!
Country [52]
0
0
India
Query!
State/province [52]
0
0
Mumbai
Query!
Country [53]
0
0
India
Query!
State/province [53]
0
0
Mysore
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Napoli
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Padova
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Roma
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
San Giovanni Rotondo
Query!
Country [58]
0
0
Mexico
Query!
State/province [58]
0
0
Coahuila
Query!
Country [59]
0
0
Mexico
Query!
State/province [59]
0
0
Distrito Federal
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Nuevo Leon
Query!
Country [61]
0
0
Netherlands
Query!
State/province [61]
0
0
Amsterdam
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Groningen
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Rotterdam
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Katowice
Query!
Country [65]
0
0
Puerto Rico
Query!
State/province [65]
0
0
Ponce
Query!
Country [66]
0
0
South Africa
Query!
State/province [66]
0
0
Kwa Zulu Natal
Query!
Country [67]
0
0
South Africa
Query!
State/province [67]
0
0
Western Cape
Query!
Country [68]
0
0
Switzerland
Query!
State/province [68]
0
0
Bern
Query!
Country [69]
0
0
Switzerland
Query!
State/province [69]
0
0
Lausanne
Query!
Country [70]
0
0
Switzerland
Query!
State/province [70]
0
0
Zuerich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this clinical research study is to learn if abatacept can improve signs and
symptoms of active Crohn's Disease in patients who have not had an adequate response to other
therapies. The safety of this treatment will also be studied.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00406653
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00406653
Download to PDF